Trial of redirected HBV-targeting T cells for liver cancer
Part of Cancer, Digestive system, Infections clinical trials.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) in the liver that can be measured and can’t be treated with standard options or those options already didn’t work
- Your hepatitis B test shows HBsAg positive
- Your liver scarring is not severe: you have no cirrhosis, or “compensated” cirrhosis (Child-Pugh A only)
- Your general health is fairly good (ECOG 0 to 1) and you have at least 3 months of expected survival
- Your blood type markers fit the needed T-cell targeting pattern (HLA class 1 matching, specifically HLA-A*02:01 or HLA-A*24:02)
- You cannot have certain recent treatments, medicines, or infections that could interfere with the study or make side effects more likely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This trial tests lab-made immune T cells that target hepatitis B (HBV) using a treatment called LioCyx-M, either alone or with lenvatinib. It’s for people with advanced HBV-related hepatocellular carcinoma (liver cancer) who can’t be cured with surgery or local procedures.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial tests a new immune cell therapy (gamma-delta T cells) combined with other drugs for people with liver cancer who have not had treatment before. It may help shrink the tumor or slow its growth.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This trial tests a new combination therapy using special immune cells (gamma-delta T cells) along with targeted drugs and immunotherapy for people with advanced liver cancer that is no longer responding to standard treatment. The goal is to see if this approach can help shrink tumors or slow their growth.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.